Pfizer, Express Scripts Clash Over Biosimilar Formulary Placement

Pfizer VP blames rebate strategies of innovators for difficulty in getting biosimilars on formularies while Express Scripts official says it is all about net cost during House hearing on lowering Rx drug prices.

medical-collage

More from Market Access

More from Pink Sheet